Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Medlive Technology Co., Ltd. ( (HK:2192) ).
Medlive Technology Co., Ltd. reported that all resolutions at its annual general meeting held in Beijing on 15 May 2026 were duly passed by poll, with shareholder participation covering the company’s entire issued share capital eligible to vote. The meeting approved the 2025 audited financial statements, a final dividend, director re-elections and remuneration, the appointment of Deloitte Touche Tohmatsu as auditor, share repurchase and issuance mandates, and amendments to the company’s memorandum and articles of association, signaling solid shareholder support for the current governance and capital management framework.
Shareholders overwhelmingly backed the re-election of key board members, including Mr. Tian Lixin and Mr. Kazutaka Kanairo, though the vote for Mr. Richard Yeh drew a comparatively higher level of opposition. The approval of general mandates to repurchase up to 10% and issue up to 20% of the company’s share capital, as well as the adoption of updated constitutional documents, provides the board with greater flexibility in capital allocation and corporate structuring, potentially influencing future financing and strategic initiatives.
More about Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 2192. The company operates in the healthcare and medical technology space, serving stakeholders through its China-based operations and corporate headquarters in Beijing’s Chaoyang District.
Average Trading Volume: 2,125,910
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.23B
For a thorough assessment of 2192 stock, go to TipRanks’ Stock Analysis page.